Form 4 for DFTX Definium Therapeutics, Inc.
Accepted 2024-08-22 00:00:00 ET · period of report 2024-08-21 · accession 0000950170-24-099872 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-08-22 | 2024-08-21 | DFTX | Halperin Wernli Miri | Executive Pres | F - Tax | $6.17 | -32.6K | 202.4K | -14% | -$201.1K |
| D | 2024-08-22 | 2024-08-21 | DFTX | Halperin Wernli Miri | Executive Pres | M - OptEx | $3.70 | +50.0K | 235.0K | +27% | +$185.0K |
| D | 2024-08-22 | 2024-08-21 | DFTX | Halperin Wernli Miri | Executive Pres | M - OptEx | $0.00 | -50.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2024-08-21 | F | D | 32,595 | $6.17 | 202,405 | D | — | — | (F2) Transaction represents a "net exercise" of an outstanding stock option to purchase an aggregate of 50,000 common shares of the Issuer granted on February 27, 2020. The Reporting Person received 17,405 common shares of the Issuer on the net exercise of the stock option. The Issuer withheld 32,595 common shares underlying the stock option for payment of the exercise price and tax withholding using a stock price of $6.17, which represents the closing price of the Issuer's common shares on August 20, 2024, the day before the exercise. |
| 2 | Common | Common Shares | 2024-08-21 | M | A | 50,000 | $3.70 | 235,000 | D | — | — | (F1) Exercise of Reporting Person's stock option that would otherwise expire February 27, 2025. |
| 3 | Derivative | Stock Option (Right to Buy) | 2024-08-21 | M | D | 50,000 | $0.00 | 0 | D | $3.70 · — to 2025-02-27 | 50,000 Common Shares | (F3) Represents the option to purchase 50,000 common shares of the Issuer, which vested over a period of four years following the date of the grant of February 27, 2020. All such options are fully vested. |